Drug intelligence / Profile preview

CVM150

Development stage: Phase 1
Lead developer: CyanVac
Modality: Vaccines & Immunotherapeutics
Administration: Intranasal

Overview

CVM150 is an investigational intranasal mumps virus vaccine candidate. It is designed to induce immunity against mumps infection through mucosal delivery. The vaccine is being developed by CyanVac and is currently in phase 1 clinical trials to evaluate its safety and immunogenicity in healthy adults. The vaccine leverages a live viral vector platform to deliver mumps virus antigens, aiming to stimulate both systemic and mucosal immune responses[1][2][3][5][9].

Brand names: CVM150CVM-150CVM 150
Other names: CVM 150CVM150CVM-150

Beyond the preview

Go deeper on CVM150.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CVM150.

Explore the full profile